Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR

PDGFRβ:5 nM (Ki), FLK1:6 nM (Ki)

在之前为正常血压的治疗犬开始使用toceranib phosphate治疗后，其收缩压显著（P = 0.0013）上升至152 mmHg ± 19，相较于基线水平136 mmHg ± 14有所增加。有37%的接受治疗的犬只发展为收缩压≥ 160 mmHg。治疗犬在开始治疗时，系统性高血压（37%）和蛋白尿（21%）的发生率与年龄相匹配的健康对照组（分别为15% [P = 0.13] 和0% [P = 0.069]）无显著差异。

Dogs scheduled to received toceranib phosphate treatment were divided into 2 groups based on SBP recorded at screening: dogs that were normotensive were assigned to Group 2a and dogs diagnosed with HT were assigned to Group 2b. After baseline evaluation, dogs enrolled in Group 2a received toceranib phosphate at a standard dose as previously published.2 Group 2b dogs received toceranib phosphate as described, but were also treated with standard‐of‐care treatment for HT, including amlodipine besylate (0.2–0.4 mg/kg PO q 24 hours), enalapril maleate (0.5 mg/kg PO q 12 hours), or both, initiated at the discretion of the attending veterinarian. Some dogs were treated with additional medications, including corticosteroids, at the discretion of the oncologist. All dogs were re‐evaluated on Day 14 (±3 days) at which time a UPC and blood pressure measurements were performed[1].